Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Hepatology Reports
Erschienen in: Current Hepatology Reports 1/2024

01.02.2024

Sarcopenia and Frailty in Advanced Liver Disease Patients: A Comprehensive Review

verfasst von: Fariha Ilyas, Fuad Zain Aloor, Sanjaya K. Satapathy

Erschienen in: Current Hepatology Reports | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This comprehensive review explores the intricate nexus between liver and muscle disorders, with a primary focus on sarcopenia, elucidating their profound impact on clinical outcomes and patient well-being. The paper examines sarcopenia’s clinical implications, diagnostic methods, pathogenesis, and management.

Recent Findings

Recent research underscores sarcopenia as a robust predictor of adverse outcomes, affecting hospitalization rates, complications, and survival, both pre- and post-liver transplantation. Contributors to sarcopenia, including malnutrition, hyperammonemia, decreased Branched-Chain amino acids, and hormonal imbalances, are highlighted.

Summary

The review emphasizes the imperative for standardized diagnostic protocols and definitions, considering individual factors like ethnicity, gender, and age, to guide clinical practice. The study emphasizes a multifaceted patient care approach, encompassing lifestyle modifications, nutritional optimization, exercise regimens, and potential pharmacological interventions. The prospects of future research look promising in uncovering novel therapeutic strategies that can ultimately improve the lives of individuals grappling with liver disorders and sarcopenia.
Literatur
1.
Sayer AA, Cruz-Jentoft A. Sarcopenia definition, diagnosis and treatment: consensus is growing. Age Ageing. 2022;51(10):afac220.
2.
Smith C, Woessner MN, Sim M, Levinger I. Sarcopenia definition: does it really matter? Implications for resistance training. Ageing Res Rev. 2022;78:101617.PubMedCrossRef
3.
Sanchez-Rodriguez D, Marco E, Cruz-Jentoft AJ. Defining sarcopenia: some caveats and challenges. Curr Opin Clin Nutr Metab Care. 2020;23:127–32.PubMedCrossRef
4.
Dhariwal S, Roy A, Taneja S, et al. Assessment of Sarcopenia Using Muscle Ultrasound in Patients With Cirrhosis and Sarcopenic Obesity (AMUSE STUDY). J Clin Gastroenterol. 2023;57:841–7.PubMedCrossRef
5.
Liu Y, Ji F, Nguyen MH. Sarcopenia in cirrhosis: epidemiology, diagnosis, management and prognosis. Curr Opin Gastroenterol. 2023;39:131–9.PubMedCrossRef
6.
7.
• Petermann-Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, Celis-Morales C. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13:86–99. This citation is of importance as it presents findings regarding the diversity in the worldwide incidence of sarcopenia.
8.
•• Welch N, Dasarathy J, Runkana A, Penumatsa R, Bellar A, Reen J, Rotroff D, McCullough AJ, Dasarathy S. Continued muscle loss increases mortality in cirrhosis: impact of aetiology of liver disease. Liver Int. 2020;40:1178–88. This citation is of major importance as it elaborates on how various causes of liver cirrhosis influence the development of sarcopenia.
9.
Dhaliwal A, Armstrong MJ. Sarcopenia in cirrhosis: a practical overview. Clin Med (Lond). 2020;20:489–92.PubMedCrossRef
10.
Peterson SJ, Braunschweig CA. Prevalence of sarcopenia and associated outcomes in the clinical setting. Nutr Clin Pract. 2016;31:40–8.PubMedCrossRef
11.
Yuan S, Larsson SC. Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism. 2023;144:155533.PubMedCrossRef
12.
13.
14.
Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. Aliment Pharmacol Ther. 2020;51:64–77.PubMedCrossRef
15.
Kamimura H, Sato T, Natsui K, et al. Molecular mechanisms and treatment of sarcopenia in liver disease: a review of current knowledge. Int J Mol Sci. 2021;22:1425.PubMedPubMedCentralCrossRef
16.
Yang YJ, Kim DJ. An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: osteoporosis, sarcopenia, and osteoporotic sarcopenia. Int J Mol Sci. 2021;22:2604.PubMedPubMedCentralCrossRef
17.
Yoo HJ, Lee B, Jung E-A, Kim SG, Kim YS, Yoo J-J. Prevalence and risk factors of erectile dysfunction in patients with liver cirrhosis: a systematic review and meta-analysis. Hepatol Int. 2023;17:452–62.PubMedCrossRef
18.
Lai JC, Dodge JL, Kappus MR, et al. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J Hepatol. 2020;73:575–81.PubMedPubMedCentralCrossRef
19.
Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol. 2021;75(Suppl 1):S147–62.PubMedPubMedCentralCrossRef
20.
Roberts RE, Vernon SW. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am J Psychiatry. 1983;140:41–6.PubMedCrossRef
21.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-156.PubMedCrossRef
22.
Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489–95.PubMedPubMedCentralCrossRef
23.
Marasco G, Sadalla S, Vara G, Golfieri R, Festi D, Colecchia A, Renzulli M. Imaging software-based sarcopenia assessment in gastroenterology: evolution and clinical meaning. Can J Gastroenterol Hepatol. 2021;2021:6669480.PubMedPubMedCentral
24.
Luengpradidgun L, Chamroonkul N, Sripongpun P, Kaewdech A, Tanutit P, Ina N, Piratvisuth T. Utility of handgrip strength (HGS) and bioelectrical impedance analysis (BIA) in the diagnosis of sarcopenia in cirrhotic patients. BMC Gastroenterol. 2022;22:159.PubMedPubMedCentralCrossRef
25.
Kumar V, Benjamin J, Shasthry V, Subramanya Bharathy KG, Sinha PK, Kumar G, Pamecha V. Sarcopenia in cirrhosis: fallout on liver transplantation. J Clin Exp Hepatol. 2020;10:467–76.PubMedCrossRef
26.
Lindqvist C, Brismar TB, Majeed A, Wahlin S. Assessment of muscle mass depletion in chronic liver disease: dual-energy x-ray absorptiometry compared with computed tomography. Nutrition. 2019;61:93–8.PubMedCrossRef
27.
Dhaliwal A, Larson D, Hiat M, Muinov LM, Harrison WL, Sayles H, Sempokuya T, Olivera MA, Rochling FA, McCashland TM. Impact of sarcopenia on mortality in patients undergoing liver re-transplantation. World J Hepatol. 2020;12:807–15.PubMedPubMedCentralCrossRef
28.
Anand A, Mohta S, Agarwal S, Sharma S, Gopi S, Gunjan D, Madhusudhan KS, Singh N, Saraya A. European Working Group on Sarcopenia in Older People (EWGSOP2) criteria with population-based skeletal muscle index best predicts mortality in Asians with cirrhosis. J Clin Exp Hepatol. 2022;12:52–60.PubMedCrossRef
29.
Lai JC, Rahimi RS, Verna EC, et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study. Gastroenterology. 2019;156:1675–82.PubMedCrossRef
30.
Wijarnpreecha K, Werlang M, Panjawatanan P, Kroner PT, Cheungpasitporn W, Lukens FJ, Pungpapong S, Ungprasert P. Association between sarcopenia and hepatic encephalopathy: a systematic review and meta-analysis. Ann Hepatol. 2020;19:245–50.PubMedCrossRef
31.
Kim G, Kang SH, Kim MY, Baik SK. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0186990.PubMedPubMedCentralCrossRef
32.
Topan M-M, Sporea I, Dănilă M, Popescu A, Ghiuchici A-M, Lupuşoru R, Şirli R. Impact of sarcopenia on survival and clinical outcomes in patients with liver cirrhosis. Front Nutr. 2021;8:766451.PubMedPubMedCentralCrossRef
33.
Perisetti A, Goyal H, Yendala R, Chandan S, Tharian B, Thandassery RB. Sarcopenia in hepatocellular carcinoma: current knowledge and future directions. World J Gastroenterol. 2022;28:432–48.PubMedPubMedCentralCrossRef
34.
Feng Z, Zhao H, Jiang Y, He Z, Sun X, Rong P, Wang W. Sarcopenia associates with increased risk of hepatocellular carcinoma among male patients with cirrhosis. Clin Nutr. 2020;39:3132–9.PubMedCrossRef
35.
Thyloor Kenchappa S, Sharma S, Kumar M, Ghuman SS, Arora A, Ranjan P. A prospective study of prevalence and impact of sarcopenia on short-term mortality in hospitalized patients with liver cirrhosis. J Clin Exp Hepatol. 2023;13(6):946–954.
36.
Vural A, Attaway A, Welch N, Zein J, Dasarathy S. Skeletal muscle loss phenotype in cirrhosis: a nationwide analysis of hospitalized patients. Clin Nutr. 2020;39:3711–20.PubMedPubMedCentralCrossRef
37.
Welch N, Attaway A, Bellar A, Alkhafaji H, Vural A, Dasarathy S. Compound sarcopenia in hospitalized patients with cirrhosis worsens outcomes with increasing age. Nutrients. 2021;13:659.PubMedPubMedCentralCrossRef
38.
Ferreira AP, Machado MV. Impact of pretransplant frailty and sarcopenia on the post-transplant prognosis of patients with liver cirrhosis: a systematic review. Eur J Gastroenterol Hepatol. 2021;33:e883–97.PubMedCrossRef
39.
Dhaliwal A, Towey J, Lord JM, Armstrong M, Elsharkawy AM. Nutrition in liver cirrhosis: a case-based overview. Frontline Gastroenterol. 2020;11:155–61.PubMedCrossRef
40.
Van Jacobs AC. Frailty assessment in patients with liver cirrhosis. Clin Liver Dis (Hoboken). 2019;14:121–5.PubMedCrossRef
41.
Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, Carey EJ. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74:1611–44.PubMedCrossRef
42.
Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38:485–521.PubMedPubMedCentralCrossRef
43.
Carey EJ, Lai JC, Sonnenday C, et al. A North American Expert Opinion Statement on sarcopenia in liver transplantation. Hepatology. 2019;70:1816–29.PubMedCrossRef
44.
Merli M, Berzigotti A, Zelber-Sagi S, Dasarathy S, Montagnese S, Genton L, Plauth M, Parés A, European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–93.CrossRef
45.
Wang S, Limon-Miro AT, Cruz C, Tandon P. CAQ Corner: the practical assessment and management of sarcopenia, frailty, and malnutrition in patients with cirrhosis. Liver Transpl. 2023;29:103–13.PubMedCrossRef
46.
Morkane CM, Kearney O, Bruce DA, Melikian CN, Martin DS. An outpatient hospital-based exercise training program for patients with cirrhotic liver disease awaiting transplantation: a feasibility trial. Transplantation. 2020;104:97–103.PubMedCrossRef
47.
Williams FR, Berzigotti A, Lord JM, Lai JC, Armstrong MJ. Review article: impact of exercise on physical frailty in patients with chronic liver disease. Aliment Pharmacol Ther. 2019;50:988–1000.PubMedCrossRef
48.
Hiramatsu A, Aikata H, Uchikawa S, et al. Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis. Hepatol Commun. 2019;3:348–55.PubMedPubMedCentralCrossRef
49.
Son SW, Song DS, Chang UI, Yang JM. Definition of sarcopenia in chronic liver disease. Life (Basel). 2021;11:349.PubMed
Metadaten
Titel
Sarcopenia and Frailty in Advanced Liver Disease Patients: A Comprehensive Review
verfasst von
Fariha Ilyas
Fuad Zain Aloor
Sanjaya K. Satapathy
Publikationsdatum
01.02.2024
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 1/2024
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-024-00640-z

Weitere Artikel der Ausgabe 1/2024

Current Hepatology Reports 1/2024 Zur Ausgabe

ReviewPaper

Portal Vein Thrombosis in Patients with Cirrhosis

ReviewPaper

Update on HCC Surveillance in Patient With Hepatitis B Virus Infection With Focus on Biomarkers

ReviewPaper

Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies

ReviewPaper

Addiction and Liver Disease: Exploring the Complex Relationship and Implications for Clinical Management

Review

Systemic Disease and Portal Hypertension

ReviewPaper

Precision Management of Patients with HBV Infection

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise